Perspective Therapeutics, Inc. CATX
0.81 USD -0.04 (-5.18%)
Nov 10, 2026, 12:32 PM EST
0.80 Day range 0.906
0.78 52-week range 6.16
- YTD
- -70.50%
- 1 year
- -63.45%
News
benzinga.com Truist Securities Maintains Buy on Perspective Therapeutics, Lowers Price Target to $8 Truist Securities analyst Gregory Renza maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target from $11 to $8.
benzinga.com Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results Perspective Therapeutics Inc (NYSE:CATX) on Monday posted a narrower loss for the third quarter.
benzinga.com Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results Perspective Therapeutics narrowed its Q3 loss to $0.27/share, but sales fell. Analysts cut price targets, sending shares down 2.4%.
benzinga.com Wedbush Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $7 Wedbush analyst David Nierengarten maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price target from $9 to $7.
benzinga.com Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $8 Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $14 to $8.
benzinga.com Reported Earlier, Perspective Therapeutics Says Bamzireotide Delivers 37% ORR In All 68 Treated NET Patients, 91% Disease Control, Median Follow-Up Up To 128 Weeks; Grade 3 TEAEs In 29%, No Grade 4 Or 5 Events Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across…- benzinga.com RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4 RBC Capital analyst Leonid Timashev downgrades Perspective Therapeutics (AMEX:CATX) from Outperform to Sector Perform and lowers the price target from $14 to $4.
benzinga.com Perspective Therapeutics Announces Interim Data From Its Current Phase 1/2a Clinical Study Of [212Pb]VMT-α-NET In Patients With Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors At ESMO Congress 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced systemic treatments
benzinga.com Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease have limited treatment options. [²¹²Pb]PSV359 is an investigational FAP-targeted alpha-particle…- benzinga.com BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
benzinga.com Perspective Therapeutics Reveals Acceptance Of [212Pb]VMT01 Data For Presentation At SITC 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
benzinga.com Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
benzinga.com Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
benzinga.com This $3 Biotech Could Be Worth $11.45, Analyst Says William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
benzinga.com William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating.- benzinga.com Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
- benzinga.com Perspective Therapeutics Enters Clinical Trial Collaboration With Merck To Combine Its PSV359 With Keytruda Under An Amendment To Ongoing Phase 1/2A Study Of PSV359 In Patients With Certain Types Of Non-Small Cell Lung Cancer And Colorectal Cancer Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
- benzinga.com BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11 BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
- benzinga.com B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5 B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.
benzinga.com Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14 Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $16 to $14.- benzinga.com Perspective Therapeutics Q2 EPS $(0.22) Beats $(0.26) Estimate, Sales $81.000K Miss $83.154K Estimate Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 26.67 percent increase over losses…
- benzinga.com Perspective Therapeutics Receives European Commission Orphan Designation For VMT-α-NET To Treat Gastroenteropancreatic Neuroendocrine Tumors The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).Orphan medicinal product designation by the EC may provide…
- benzinga.com Perspective Therapeutics' Updated Data On Its [212Pb]VMT-α-NET Program Accepted For Presentation At European Society Of Medical Oncology Congress 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
benzinga.com Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-market. Other stocks moving lower in pre-market.
benzinga.com Perspective Doses First Brain Tumor Patient in Radiopharmaceutical Study, Expands Cancer Drug Trial to Meningioma Patients Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the…- benzinga.com Perspective Therapeutics Reports Early Response SignalS And Favorable Safety Across Three Radiopharmaceutical Programs At ASCO 2026, Including 29% Response Rate In Advanced Melanoma Cohort One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily…
- benzinga.com Perspective Therapeutics Announces That The First Patients Were Dosed In Two New Cohorts Of Phase 1/2a Studies In Neuroendocrine Tumors And Solid Tumors, Respectively The first patient was treated with [212Pb]VMT-α-NET in a fourth cohort of the Company's ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin…
- benzinga.com Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $76.000K Miss $136.917K Estimate Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.31) by 19.35 percent. This is unchanged from the same period last…
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
- benzinga.com BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
- benzinga.com Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
- benzinga.com Perspective Therapeutics Reports 72% Of Patients Alive Without Disease Progression In Early Cancer Trial, Says 43% Of Patients Show Tumor Response With New Radiotherapy Treatment Perspective Therapeutics, Inc. ("Perspective" or the "Company) (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced…
- benzinga.com HC Wainwright & Co. Maintains Buy on Perspective Therapeutics, Raises Price Target to $13 HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $12 to $13.
- benzinga.com B. Riley Securities Maintains Buy on Perspective Therapeutics, Raises Price Target to $13 B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $11 to $13.
- benzinga.com UBS Maintains Buy on Perspective Therapeutics, Raises Price Target to $8 UBS analyst David Dai maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $7 to $8.
- benzinga.com Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
- benzinga.com Perspective Therapeutics To Present Updated [212Pb]VMT-α-NET Data At AACR 2026 Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced…
- benzinga.com RBC Capital Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $14 RBC Capital analyst Leonid Timashev maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price target from $18 to $14.
- benzinga.com BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
- benzinga.com Perspective Therapeutics Q4 EPS $(0.51) Misses $(0.36) Estimate, Sales $43.000K Miss $215.615K Estimate. Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.36) by 42.06 percent. This is a 15 percent increase over losses…
- benzinga.com Earnings Scheduled For March 16, 2026
benzinga.com This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - benzinga.com Piper Sandler Initiates Coverage On Perspective Therapeutics with Overweight Rating, Announces Price Target of $16 Piper Sandler analyst Biren Amin initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Overweight rating and announces Price Target of $16.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com HC Wainwright & Co. Maintains Buy on Perspective Therapeutics, Raises Price Target to $12 HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $10 to $12.
- benzinga.com Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
- benzinga.com Perspective Therapeutics Announces 2026 Strategic Priorities With VMT-α-NET Progress, Planned Conference Submissions, Regulatory Engagement, And Mid-To-Late 2026 Updates Across Clinical Pipeline Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in…